PEDIATRICS Vol. 90 No. 2 August 1992, pp. 186-189
This Article
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huseman, C. A.
Right arrow Articles by Angle, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huseman, C. A.
Right arrow Articles by Angle, C. R.

Neuroendocrine Effects of Toxic and Low Blood Lead Levels in Children

Carol A. Huseman MD1, Madan M. Varma PhD2, and Carol R. Angle MD1

1 From the University of Nebraska Medical Center, Omaha
2 From the School of Medicine, University of Missouri at Kansas City

From 3 million to 4 million children In America have lead poisoning. This environmental toxin affects 1 in every 6 children younger than 6 years of age in the United States. The marked effects of lead toxicity on the central nervous system are well known, ie, lowering IQ and impairing memory, reaction time, and the ability to concentrate. Children are at greatest risk for the central nervous system effects of lead because the central nervous system is at its peak in development during the first few years of life. The negative correlation of stature and blood lead level (bPb) found in the National Health and Nutrition Examination Survey directed the authors to evaluate the possible neuroendocrine effects of this toxin in children. Twelve children were studied during toxic(ge40 µg/dL) and low bPb (<40 µg/dL). Classic provocative stimuli, l-dopa (15 mg/kg by mouth) and insulin (0.1 U/kg given intravenously), were used to determine human growth hormone (hGH) responses during toxic bPb and after chelation therapy in six of the subjects. An additional four subjects were studied during low bPb. In two patients LGH levels were determined every 20 minutes for 24 hours during toxic bPb. Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone were also determined. All children studied showed growth retardation during toxic bPb. Mean peak hGH responses to provocative stimuli were lower during toxic bPb, but the responses were all within normal limits. The mean 24-hour hGH values were low in the two patients (0.8 ± 0.2 [SE] ng/mL and 2.0 ± 0.8 ng/mL) studied compared with normal control patients (6.4 ± 0.3 ng/mL). Insulin-like growth factor I values showed an inverse correlation with toxic blood bPb, up to 40 µg/dL. Basal thyroid-stimulating hormone, prolactin, thyroxine, and triiodothyronine concentrations were not affected by bPb. In addition, thyrold-stimulating hormone and prolactin responses to thyrotropin-releasing hormone were not affected by toxic or low bPb. Cortisol responses to insulin-induced hypoglycemia were normal (P le .05). These observations, taken together, confirm the inadequacy of acute hGH responses to secretagogue as a reliable indicator of hGH secretion and indicate that lead-induced short stature may be due to diminished hGH secretion, which in turn results in reduced insulin-like growth factor I secretion, or that Pb may also directly inhibit insulin-like growth factor I formation.

Key Words: lead toxicity • neuroendocrine effects • growth

Submitted on July 26, 1991
Accepted on December 29, 1991